Literature DB >> 2061983

Pathophysiology and treatment of septic shock.

E C Rackow1, M E Astiz.   

Abstract

The mortality from septic shock continues to range between 40% to 60% despite advances in cardiovascular support and antibiotic therapy. Impairment of host defenses predisposes to the development of both severe infection and septic shock. The activation of a myriad of cellular and plasma mediators by microbial toxins produces the systemic and metabolic manifestations of sepsis. The clinical presentation includes characteristic clinical, hemodynamic, and laboratory abnormalities. Multiple organ systems are involved during septic shock, with outcome dependent on the circulatory response and the development of sequential organ failures. Initial resuscitation is directed at restoring tissue perfusion with fluids and vasoactive drugs, guided by assessment of the patient's hemodynamic status. Identification of the site of infection and choice of appropriate antibiotics are critical to the success of therapy. Newer therapeutic modalities include immunologic interventions that attenuate mediator activity and modulate the immune response. Pharmacologic therapies are also being developed that are aimed at blocking the actions of specific mediators.

Entities:  

Mesh:

Year:  1991        PMID: 2061983

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  21 in total

Review 1.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.

Authors:  Emanuel P Rivers; Lauralyn McIntyre; David C Morro; Kandis K Rivers
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

2.  Effects of increased red cell mass on subclinical tissue acidosis in hyaline membrane disease.

Authors:  E F La Gamma; A Krauss; P A Auld
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-09       Impact factor: 5.747

3.  The effect of N-acetylcysteine on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients.

Authors:  Z Molnar; K L MacKinnon; E Shearer; D Lowe; I D Watson
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

4.  Rolipram improves renal perfusion and function during sepsis in the mouse.

Authors:  Joseph H Holthoff; Zhen Wang; Naeem K Patil; Neriman Gokden; Philip R Mayeux
Journal:  J Pharmacol Exp Ther       Date:  2013-09-09       Impact factor: 4.030

5.  Thaliporphine increases survival rate and attenuates multiple organ injury in LPS-induced endotoxaemia.

Authors:  Chin-Wei Chiao; Shoei-Sheng Lee; Chin-Chen Wu; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-15       Impact factor: 3.000

Review 6.  Sepsis and septic shock. II. Treatment.

Authors:  J Mayer; R Hajek; J Vorlicek; M Tomiska
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

Review 7.  Gram-negative sepsis: a dilemma of modern medicine.

Authors:  R C Bone
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

Review 8.  Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.

Authors:  Hilmar Burchardi; Heinz Schneider
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis.

Authors:  T Evans; A Carpenter; A Silva; J Cohen
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

Review 10.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.